We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 304.00
Bid: 301.00
Ask: 304.00
Change: 14.00 (4.83%)
Spread: 3.00 (0.997%)
Open: 310.00
High: 314.00
Low: 304.00
Prev. Close: 290.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Chi-Med to Attend Upcoming Investor Conferences

11 May 2020 07:00

RNS Number : 3486M
Hutchison China Meditech Limited
11 May 2020
 

Press Release

Chi-Med to Attend Upcoming Investor Conferences

London: Friday, May 11, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of Chi-Med, will participate in a virtual fireside chat at the Bank of America 2020 Health Care Conference on Thursday, May 14, 2020 9:40 a.m. Eastern Daylight Time (EDT).

 

The discussion will be webcast live and can be accessed at www.chi-med.com in the Shareholder Information section under "Events, Circulars & Forms." Investors interested in listening to the live webcast should log on before the start time to download any software required. A replay of the event will be available shortly thereafter for approximately 90 days.

 

Members of the senior management team will also attend virtual one-on-one meetings at the Bank of America Health Care Conference on May 14, as well as during the following other conferences:

 

· Citi Virtual Pan-Asia Regional Investor Conference from Tuesday to Thursday, May 19 to 21, 2020;

 

· Jefferies Virtual Global Healthcare Conference from Tuesday to Thursday, June 2 to 4, 2020; and

 

· Goldman Sachs Global Healthcare Conference Webcast from Tuesday to Thursday, June 9 to 11, 2020.

 

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.

 

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

 

CONTACTS

Investor Enquiries

Mark Lee, Senior Vice President

+852 2121 8200

Annie Cheng, Vice President

+1 (973) 567 3786

Media Enquiries

 

Americas - Brad Miles, Solebury Trout

+1 (917) 570 7340 (Mobile) bmiles@troutgroup.com

Europe - Ben Atwell / Alex Shaw, FTI Consulting

+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)Chi-Med@fticonsulting.com

Asia - Joseph Chi Lo / Zhou Yi, Brunswick

+852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 9783 6894 (Mobile), yzhou@brunswickgroup.com

Nominated Advisor

Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited

+44 (20) 7886 2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAMZGGKRRZGGZG
Date   Source Headline
6th Feb 20207:20 amRNSIssue of Equity
4th Feb 20204:40 pmRNSSecond Price Monitoring Extn
4th Feb 20204:35 pmRNSPrice Monitoring Extension
31st Jan 20207:00 amRNSNotice of Results
29th Jan 20207:25 amRNSHolding(s) in Company
23rd Jan 20207:35 amRNSPricing of US$110 Million Public Offering of ADSs
22nd Jan 20207:00 amRNSChi-Med Announces Proposed Offering of ADSs
20th Jan 202010:40 amRNSPositive SANET-p Phase III Clinical Trial Results
13th Jan 20207:00 amRNSChi-Med Starts Surufatinib+PD-1 Ph2 Combo Trial
6th Jan 20207:04 amRNSChi-Med to Present at JP Morgan Conference
31st Dec 20197:00 amRNSBlock Listing Six Monthly Return
31st Dec 20197:00 amRNSTotal Voting Rights
20th Dec 20197:00 amRNSSurufatinib Granted Priority Review in China
12th Dec 20198:57 amRNSGrant of share options
29th Nov 20198:56 amRNSTotal Voting Rights
28th Nov 20197:00 amRNSElunate® Included in China NRDL
25th Nov 20197:47 amRNSChi-Med Highlights Presentations at 2019 ESMO Asia
25th Nov 20197:00 amRNSSurufatinib granted FDA orphan drug designation
11th Nov 20197:00 amRNSSurufatinib China NDA acceptance
17th Oct 20197:26 amRNSChi-Med Ph II gastric cancer data for Savolitinib
10th Oct 201910:22 amRNSGrant of share options under share option scheme
10th Oct 20199:00 amRNSInnovent and Chi-Med Expand Global Collaboration
4th Oct 20197:11 amRNSChi-Med Phase I/Ib Trial of HMPL-523 in Lymphoma
3rd Oct 20198:26 amRNSHolding(s) in Company
30th Sep 20191:49 pmRNSHolding(s) in Company
30th Sep 201912:11 pmRNSHolding(s) in Company
30th Sep 20197:00 amRNSChi-Med Surufatinib Phase III data at ESMO
30th Sep 20197:00 amRNSTotal Voting Rights
25th Sep 20197:00 amRNSChi-Med Presents SANET-ep Phase III data at ESMO
18th Sep 20197:00 amRNSChi-Med Highlights Presentations at 2019 CSCO
3rd Sep 20197:19 amRNSChi-Med to present at MS conference
3rd Sep 20197:00 amRNSChi-Med initiates Phase I trial
30th Aug 20197:00 amRNSTotal Voting Rights
23rd Aug 20197:00 amRNSStart of Clinical Trial in China
20th Aug 20197:48 amRNSHolding(s) in Company
30th Jul 201910:48 amRNSTR-1: Form for notification of major holdings
30th Jul 20197:00 amRNS2019 Interim Results and Clinical Programs Update
10th Jul 20194:35 pmRNSPrice Monitoring Extension
3rd Jul 20197:00 amRNSChi-Med to Announce 2019 Half-Year Results
3rd Jul 20197:00 amRNSTR-1: Form for notification of major holdings
28th Jun 201911:10 amRNSBlocklisting Six Monthly Return
28th Jun 201910:07 amRNSPricing of U.S. Public Secondary Offering of ADSs
28th Jun 20197:00 amRNSSecondary Offering of American Depositary Shares
21st Jun 20194:40 pmRNSSecond Price Monitoring Extn
21st Jun 20194:35 pmRNSPrice Monitoring Extension
19th Jun 20194:35 pmRNSPrice Monitoring Extension
14th Jun 20199:00 amRNSSurufatinib Phase III Study Meets Primary Endpoint
12th Jun 20199:18 amRNSBlock Admission Applications & Total Voting Rights
10th Jun 201912:07 pmRNSSecond Price Monitoring Extn
10th Jun 201912:02 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.